La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

ProMIS Neurosciences Gestione

Gestione criteri di controllo 4/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Neil K. Warma

Amministratore delegato

US$40.0k

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	less than a year
Proprietà del CEO	n/a
Durata media del management	4.9yrs
Durata media del Consiglio di amministrazione	6.9yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Neil K. Warma (61 yo)

less than a year

Mandato

US$40,000

Compensazione

Mr. Neil K. Warma, MBA, is President, Principal Executive Officer and Director of ProMIS Neurosciences, Inc. December 30, 2023 and served as its Independent Director since May 13, 2021 until December 30, 2...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Eugene Williams	Co-Founder & Chairman	9.3yrs	US$275.00k	0.54% $ 204.7k
Neil K. Warma	President	less than a year	US$40.00k	Nessun dato
Neil Cashman	Co-Founder	20.3yrs	US$378.82k	0.38% $ 147.1k
Gavin Malenfant	Chief Operating Officer	2.9yrs	US$435.90k	0.0089% $ 3.4k
Daniel Geffken	Chief Financial Officer	7.5yrs	US$142.40k	0.020% $ 7.5k
Johanne Kaplan	Chief Development Officer	8.2yrs	US$525.57k	0.016% $ 6.2k
Ernest Bush	Head of Pharmacology/Toxicology & Senior Consultant	6.4yrs	Nessun dato	Nessun dato
David Wishart	Chief Physics Officer	3.3yrs	Nessun dato	Nessun dato
Dennis Chen	Head of Manufacturing & Senior Consultant	no data	Nessun dato	Nessun dato
Larry Altstiel	Chief Medical Officer	2.4yrs	Nessun dato	Nessun dato

4.9yrs

Durata media

65yo

Età media

Gestione esperta: Il team dirigenziale di PMN è considerato esperto (durata media dell'incarico 4.8 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Eugene Williams	Co-Founder & Chairman	9.3yrs	US$275.00k	0.54% $ 204.7k
Neil K. Warma	President	3.3yrs	US$40.00k	Nessun dato
Neil Cashman	Co-Founder	17.7yrs	US$378.82k	0.38% $ 147.1k
Timothy Rothwell	Member of Business Advisory Board	5.6yrs	Nessun dato	Nessun dato
William Wyman	Independent Director	10.5yrs	US$40.00k	0.21% $ 80.6k
Nigel Burns	Member of Business Advisory Board	no data	Nessun dato	Nessun dato
Michael Higgins	Member of Business Advisory Board	no data	Nessun dato	Nessun dato
William Mobley	Member of Scientific Advisory Board	7.3yrs	Nessun dato	Nessun dato
Charles Olanow	Member of Scientific Advisory Board	5.3yrs	Nessun dato	Nessun dato
Patrick Kirwin	Independent Director	9.3yrs	US$40.00k	0.33% $ 126.8k
Sharon Cohen	Member of Scientific Advisory Board	6.5yrs	Nessun dato	Nessun dato
Madge Shafmaster	Lead Independent Director	3yrs	US$40.00k	0.70% $ 266.7k

6.9yrs

Durata media

66yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di PMN sono considerati esperti (durata media dell'incarico 6.8 anni).

ProMIS Neurosciences Gestione

Gestione criteri di controllo 4/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

ProMIS Neurosciences, Inc., Annual General Meeting, Jun 13, 2024

ProMIS Neurosciences Appoints Gail M. Farfel as Chief Executive Officer

ProMIS Neurosciences, Inc. Appoints Larry Altstiel as Chief Medical Officer

ProMIS Neurosciences, Inc. Announces Board Appointments

ProMIS Neurosciences Appoints Cheryl Wellington to its Scientific Advisory Board

ProMIS Neurosciences Adds Dr. David Wishart to Its Scientific Advisory Board

Recent updates

ProMIS Neurosciences Announces Data on the Pathogenic Role of Toxic Misfolded SOD1 Aggregates in ALS Published in Acta Neuropathologica and Open Biology

ProMIS Neurosciences, Inc. Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer's Association International Conference

ProMIS Neurosciences, Inc. announced that it expects to receive CAD 30.3 million in funding from Great Point Partners, LLC, Armistice Capital LLC, Ally Bridge Group, Sphera Funds Management Ltd and other investors

ProMIS Neurosciences, Inc. Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial

ProMIS Neurosciences Receives Written Notice from Nasdaq Due to Non-Compliance with Nasdaq Listing Rule 5550(b)(2)

ProMIS Neurosciences, Inc. Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies

ProMIS Neurosciences Inc. Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as A Treatment Target for ALS

ProMIS Neurosciences, Inc., Annual General Meeting, Jun 13, 2024

ProMIS Neurosciences, Inc. has filed a Follow-on Equity Offering in the amount of $25 million.

ProMIS Neurosciences, Inc. has filed a Follow-on Equity Offering in the amount of $25 million.

ProMIS Neurosciences Announces Publication on Novel Target for ALS

Promis Neurosciences Inc. Doses First Subjects in Phase 1A Clinical Trial of PMN310 to Treat Alzheimer's Disease

ProMIS Neurosciences to Delist from TSX

ProMIS Neurosciences Inc. Announces FDA Clearance of Investigational New Drug Application for PMN310 in Alzheimer’s Disease

ProMIS Neurosciences, Inc. announced that it has received $7.472277 million in funding from Kraft Group LLC and other investors

ProMIS Neurosciences Appoints Gail M. Farfel as Chief Executive Officer

ProMIS Neurosciences, Inc. to Present At 2022 Alzheimer's Association International Conference

ProMIS Neurosciences Common Shares Deleted from Other OTC

ProMIS Neurosciences, Inc. Appoints Larry Altstiel as Chief Medical Officer

ProMIS Neurosciences, Inc. Announces Pmn310 Antibody Demonstrates Significant Cognitive Benefit in A Mouse Model of Alzheimer’s Disease

ProMIS Neurosciences, Inc. Announces Board Appointments

ProMIS Neurosciences Appoints Cheryl Wellington to its Scientific Advisory Board

ProMIS Neurosciences, Inc. Initiates Program to Develop Monoclonal Antibodies to Treat Schizophrenia and Other Chronic Mental Illnesses

ProMIS Neurosciences, Inc. has completed a Composite Units Offering in the amount of $17.5 million.

ProMIS Neurosciences, Inc. Initiates Commercialization of Covid-19 Serology Assay

ProMIS Neurosciences Re-Initiates Path to IND for PMM310 with Producer Cell Line Development

ProMIS Neurosciences, Inc. announced that it has received CAD 8.75 million in funding from Kraft Group LLC and other investors

ProMIS Neurosciences, Inc. Announces Perspectives on Recent Progress in the Alzheimer's Field

ProMIS Neurosciences Adds Dr. David Wishart to Its Scientific Advisory Board

ProMIS Neurosciences, Inc. Presents Lead Program for Alzheimer's Disease at Prestigious Keystone Symposia Scientific Conference

ProMIS Neurosciences, Inc. Announces Resignation of Anthony Giovinazzo from the Board of Directors

ProMIS Neurosciences, Inc. to Develop Multivalent Vaccine for Alzheimer’s Disease

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media